Millipore and Proteome Sciences Announce Licensing Agreement

08-Jul-2009 - United Kingdom

Millipore Corporation and Proteome Sciences plc announced they have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer’s disease. Under the terms of the agreement, Millipore will develop Luminex bead-based multiplex immunoassays to measure Proteome Sciences’ proprietary Alzheimer’s disease biomarkers. The ability to quickly test for these biomarkers will enable researchers to develop new drugs and diagnostics to treat and monitor patients with Alzheimer’s.

Proteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer’s disease working in collaboration with the Institute of Psychiatry (IoP) at King’s College London. A number of these biomarkers have been independently identified and their relationship to Alzheimer’s disease confirmed by researchers at GlaxoSmithKline.

Millipore will acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer’s disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers. Financial terms of the license agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper